Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2018 | Fourth generation TKIs for CML: asciminib

Michael Mauro • 12 Sep 2018
SOHO 2018
Chronic Myeloid Leukemia Leukemia Asciminib Bosutinib

Tyrosine kinase inhibitors (TKIs) are the standard first-line treatment for patients with chronic myeloid leukemia (CML). At the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting held in Houston, TX, Michael Mauro, MD, of the Memorial Sloan Kettering Cancer Center, New York City, NY, discusses the recent developments in TKI therapy, including his team’s Phase III trial comparing asciminib, a fourth generation TKI, which acts as an allosteric inhibitor, to bosutinib (NCT03106779). Dr Mauro highlights key unmet needs in CML therapy, such as patients showing resistance or intolerance to TKIs; thus emphasizing the importance of these trials.

More from Michael Mauro

6:31
An overview of trials investigating asciminib in the treatment of Ph+ CML
Michael Mauro • 18 Dec 2023
2:26
ASCEMBL: asciminib versus bosutinib in third-line treatment of CP-CML
Michael Mauro • 18 Dec 2023
1:14
Unmet needs in pediatric CML
Michael Mauro • 22 Oct 2022
1:52
ESH CML session highlights: pediatrics, biomarkers, and COVID
Michael Mauro • 22 Oct 2022

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals